CADTH Canadian Drug Expert Committee recommendation. Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis.

CADTH Canadian Drug Expert Committee recommendation. indication: relapsing-remitting multiple sclerosis. Daclizumab (Zinbryta -- Biogen Canada Inc.) :

Show other versions (1)

The Canadian Drug Expert Committee (CDEC) recommends that Daclizumab be reimbursed for the treatment of adult patients with active relapsing-remitting multiple sclerosis (RRMS) who have had an inadequate response to, or who are unable to tolerate, one or more therapies indicated for the treatment of...

Full description

Saved in:
Bibliographic Details
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: [Ottawa, Ontario] : Canadian Agency for Drugs and Technologies in Health, June 2017.
Edition:Version 1.0.
Series:Common drug review clinical review report.
Subjects:
Multiple Sclerosis, Relapsing-Remitting > drug therapy.
Daclizumab > therapeutic use.
Daclizumab > economics.
Daclizumab > administration & dosage.
Insurance, Health, Reimbursement > economics.
Cost-Benefit Analysis.
Canada.
Online Access:http://www.ncbi.nlm.nih.gov/books/NBK535204/
Full text
http://www.ncbi.nlm.nih.gov/books/NBK535204/
Full text

MCPHS

Holdings details from MCPHS
Call Number: NCBI

Similar Items